Aarkstore - Multiple Myeloma (Kahlers Disease)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Aarkstore - Multiple Myeloma (Kahlers Disease)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Description:

Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Multiple Myeloma (Kahler's Disease). Browse full report @ – PowerPoint PPT presentation

Number of Views:26

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Multiple Myeloma (Kahlers Disease)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015


1
Multiple Myeloma (Kahlers Disease)-Global API
Manufacturers, Marketed and Phase III Drugs
Landscape, 2015
Category Pharmaceuticals and Healthcare
2
Multiple Myeloma (Kahler's Disease)-Global API
Manufacturers, Marketed and Phase III Drugs
Landscape, 2015, Report provides comprehensive
insights about phase III pipeline drugs and
marketed drugs across the Multiple Myeloma
(Kahler's Disease). A key objective of
DelveInsights report is to establish the
understanding for API Manufacturers for marketed
and Phase III Pipeline drugs across the different
countries and regions for the drugs falling under
Multiple Myeloma (Kahler's Disease). The Report
gives insights into patents providing thepatent
protection data and marketing exclusivity of all
the drugs across the Multiple Myeloma (Kahler's
Disease). While the leading brands, companies and
chemicals are considered thoroughly,
DelveInsights report also provides details on the
Global API Manufacturersacross the globe
coveringDrug Master FilingsofUS, Europe and API
Manufacturers in Asia specifically China and
India. The researchanalysis also presents the
global sales forecasts data till 2016.
Browse Complete Report http//www.aarkstore.com
/pharmaceuticals-healthcare/97800/multiple-myeloma
-kahlers-disease-global-api-manufacturers-marketed
-and-phase-iii-drugs-landscape-2015
3
Data Sources
  • The report is built using data and information
    sourced from proprietary databases, primary and
    secondary research and in-house analysis by
    DelveInsight team of industry experts.
  • Secondary sources information and data has been
    collected from various printable and
    non-printable sources like search engines, News
    websites, Government Websites, Trade Journals,
    White papers, Magazines, Trade associations,
    Books, Industry Portals, Industry Associations
    and access to available databases.
  • Please noteThis report requires certain updates.
    We have all the information available but require
    3 business days to complete the process and
    ensure it is as up-to-date as possible. Certain
    sections in the report may be removed or altered
    based on the availability and relevance of data
    for the indicated disease.
  • .

4
Scope
  • A snapshot of the global Market therapeutics
    scenario for Multiple Myeloma (Kahler's Disease).
  • A review of the marketed products under
    prescription for Multiple Myeloma (Kahler's
    Disease), regulatory information and marketing
    status.
  • Coverage of global patent coverage and detailed
    commentaries on the US patent challenges.
  • Graphical representation of investigational
    products for patent expiry and market
    exclusivities across the globe.
  • Product profiles for marketed products for
    Multiple Myeloma (Kahler's Disease) with complete
    description of mechanism of action, therapeutic
    class, target, route(s) of administration and
    chemical details.
  • Coverage of API Manufacturers for Multiple
    Myeloma (Kahler's Disease) drugs in the United
    States, Europe and Asian Regions with location
    details.
  • Coverage of Regulatory filings in theUS, Europe,
    and Asia specifically India and China for
    Multiple Myeloma (Kahler's Disease) drugs.

5
Reasons to buy
  • Evaluate the marketing status and exclusivity
    details of Multiple Myeloma (Kahler's Disease)key
    products to exploit opportunities for generic
    drug development opportunities.
  • Identify and understand important and diverse
    types of therapeutics under Phase III development
    for Multiple Myeloma (Kahler's Disease).
  • Design effective counter-strategies to gain
    competitive advantage by identifying the key
    patent expiry details and exclusivity with
    respect to Multiple Myeloma (Kahler's Disease).
  • API intelligence over marketed drugs forMultiple
    Myeloma (Kahler's Disease)and gaining primary
    intelligence over active ingredients
    manufacturers across the globe.
  • API intelligence over leading Phase III Pipeline
    drugs.
  • Develop and designstrategies by identifying the
    API manufacturers for Phase III Pipeline products
    to enhance and expand business potential and
    scope.

6
Table of Content
  • Indication Overview
  • Marketed Drugs
  • Marketed Details of Drugs by Application Type
  • Marketed Details of Drugs (NDA) by Marketing
    Status
  • Marketed Details of Drugs by Patent Expiration
    Timeline
  • Active Pharmaceutical Ingredient (API)
    Manufacturers Assessment
  • API Manufacturers by United States Drug Master
    File (US DMF) Status
  • API Manufacturers by US DMF Status (Drug
    Specific)
  • API Manufacturers in Europe by Country
  • API Manufacturers in India by State
  • API Manufacturers in China by Province
  • Marketed Details of Approved Drugs by Geography
  • Active Pharmaceutical Ingredient (API)
    Manufacturers Assessment for Phase III Pipeline
    Drugs
  • API Manufacturers by US DMF Status (Drug
    Specific)

7
List of Tables
  • Multiple Myeloma (Kahler's Disease) Therapeutic
    Market, US, Marketed Drugs by Application Type,
    2015
  • Multiple Myeloma (Kahler's Disease) Therapeutic
    Market, US, Marketed Drugs by Marketing Status,
    2015
  • Multiple Myeloma (Kahler's Disease) Therapeutic
    Market, US, (Year), 2015
  • Multiple Myeloma (Kahler's Disease) Marketed
    Drugs, API Manufacturers by US DMF Status, 2015
  • Multiple Myeloma (Kahler's Disease) Marketed
    Drugs, US DMF Status Drug Specific (Number), 2015
  • Multiple Myeloma (Kahler's Disease) Drugs, API
    Manufacturers, Europe by Country, 2015
  • Multiple Myeloma (Kahler's Disease) Drugs, API
    Manufacturers, India by State, 2015
  • Multiple Myeloma (Kahler's Disease) Drugs, API
    Manufacturers, China by Province, 2015
  •  
  •  

8
List of Figures
  • Multiple Myeloma (Kahler's Disease) Therapeutic
    Market, US, Marketed Drugs by Application Type
    (), 2015
  • Multiple Myeloma (Kahler's Disease) Therapeutic
    Market, US, Marketed Drugs by Marketing Status
    (), 2015
  • Multiple Myeloma (Kahler's Disease) Therapeutic
    Market, US, (Year), 2015
  • Multiple Myeloma (Kahler's Disease) Marketed
    Drugs, API Manufacturers by US DMF Status (),
    2015
  • Multiple Myeloma (Kahler's Disease) Marketed
    Drugs, US DMF Status Drug Specific (Number), 2015
  • Multiple Myeloma (Kahler's Disease) Drugs, API
    Manufacturers, Europe by Country, 2015
  • Multiple Myeloma (Kahler's Disease) Drugs, API
    Manufacturers, India by State, 2015
  • Multiple Myeloma (Kahler's Disease) Drugs, API
    Manufacturers, China by Province, 2015

9
Related reports
  •  
  • Skin Health Spa PLC - Strategic SWOT Analysis
    Review
  • Biovest International, Inc. (BVTIQ) - Strategic
    SWOT Analysis Review
  • Natco Pharma Limited (NATCOPHARM) - Financial and
    Strategic SWOT Analysis Review
  • AnGes MG, Inc. (4563) - Financial and Strategic
    SWOT Analysis Review
  • XOMA Corporation (XOMA) - Financial and
    Strategic SWOT Analysis Review
  • Global Epinephrine Autoinjector Market 2015-2019
  • Human Growth Hormone Market in the US 2015-2019
  • Global Acute Coronary Syndrome (ACS) Market
    2015-2019
  • Global Automated External Defibrillator Market
    2015-2019
  • Global Gaucher Disease Market 2015-2019

10
  • Multiple Myeloma (Kahlers Disease)-Global API
    Manufacturers, Marketed and Phase III Drugs
    Landscape, 2015
  • Published Feb 2015 100 Pages
  • Multiple Myeloma (Kahler's Disease)-Global API
    Manufacturers, Marketed and Phase III Drugs
    Landscape, 2015, Report provides comprehensive
    insights about phase III pipeline drugs and
    marketed drugs across the Multiple Myeloma
    (Kahler's Disease).
  • Price

Format Price
PDF 2000
Site License 4000
Enterprise Wide License 6000
11
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com